Valantine Hannah 4
4 · BridgeBio Pharma, Inc. · Filed Jun 30, 2025
Insider Transaction Report
Form 4
Valantine Hannah
Director
Transactions
- Sale
Common Stock
2025-06-26$44.01/sh−1,542$67,863→ 7,465 total - Sale
Common Stock
2025-06-26$44.11/sh−876$38,640→ 9,007 total - Sale
Common Stock
2025-06-26$44.13/sh−398$17,562→ 2,289 total(indirect: By Spouse) - Sale
Common Stock
2025-06-26$44.03/sh−1,891$83,261→ 398 total(indirect: By Spouse)
Footnotes (2)
- [F1]Represents the weighted average sale price of the shares sold from $44.025 to $44.14 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote.
- [F2]Represents the weighted average sale price of the shares sold from $44.12 to $44.13 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote.